Quantcast

Industry news that matters to you.  Learn more

Archives for October 2011

PrognosDx Health and Accium BioSciences Enter Into Collaborative and Research Agreement to Develop Clinical Tests Based on Histone Biomarkers

PrognosDx Health, a pioneering company in cancer epigenetics, announced today that Dr. Jeffrey L. Wolf has joined its scientific advisory board. An expert in multiple myeloma and other hematopoietic malignancies, Dr. Wolf also specializes in bone marrow transplantation for treatment of a variety of cancers. Dr. Wolf is the Director of the Multiple Myeloma Program in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center and a Clinical Professor of Medicine at UCSF.

It was also announced that PrognosDx Health and Accium BioSciences (Seattle, Washington) have entered into a collaboration agreement aimed at co-developing and commercializing a series of high-value predictive histone biomarker tests. The collaboration combines the expertise and breakthrough epigenetic platform technology of PrognosDx with the accelerator mass spectrometry (AMS) platform of Accium BioSciences.

Neuronetrix Helps Put ERP Biomarkers in the Spotlight at Alzheimer’s Clinical Trial Conference

Neuronetrix today announced their sponsorship of CTAD 2011 (Clinical Trials on Alzheimer’s Disease) to be held November 3-5 in San Diego, CA. CTAD will be attended by some 500 leading Alzheimer’s researchers, clinicians, and pharmaceutical representatives from around the world. A new focus this year will be a panel discussion entitled “Event-Related Potential Biomarkers for Early Diagnosis and Treatment Trials of Alzheimer’s Disease.”

Terry Fox Research Institute Aims to Change Diagnosis and Management of Ovarian Cancer Worldwide

Women throughout the world will benefit from a new, pan-Canadian Terry Fox Research Institute (TFRI) initiative that aims to change the way in which ovarian cancer is diagnosed and managed. TFRI and the Canadian Partnership Against Cancer are providing a total of $5-million in funding for a five-year, multi-site Ovarian Cancer Pan-Canadian Program called COEUR. The program will identify new biomarkers to predict and treat this relatively rare but deadly form of cancer, which will result in the use and application of current and new drugs more effectively for patients.

Clarient Joins the HistoRX Clinical Trials Network

Clarient, a GE Healthcare company, and HistoRx, Inc., have signed a definitive agreement to provide pharma services using AQUA technology to their growing lists of pharma clients. By implementing HistoRx’s AQUA technology in Clarient’s CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies’ growing need for biomarker analysis in clinical trials. Use of tissue biomarkers to characterize a patient’s tumor is becoming a crucial element of personalized cancer care. AQUA technology is an automated, quantitative IHC testing method that enables standardized precision measurement of protein biomarkers in tissue as an aid to a pathologist’s diagnosis.

Metabolomics Insight Into Periodontal Disease Published in the Journal of Dental Research

Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today the publication of “Metabolomics Revealed Elevated Macromolecular Degradation in Periodontal Disease,” in the Journal of Dental Research. Non-targeted biochemical profiling (metabolomics) provided insight into the biochemical mechanisms underlying periodontitis pathogenesis and identified potential disease biomarkers. The study was carried out by Virginia M. Barnes and colleagues of Colgate-Palmolive, and SUNY-Buffalo, School of Dental Medicine, with co-authors from Metabolon. Periodontal disease, described as inflammation of the gums, is among the most common infectious diseases.